Amyloidosis under a microscope, cell image, green overlay

Rare diseases Nexus

Congress highlights

Last updated: 25th Feb 2026

Published: 25th Feb 2026

Browse articles and videos featuring expert insights from the latest scientific meetings and congresses.

A female healthcare professional, with brown hair and wearing glasses, looks at her laptop in front of her.

Downloadable infographic

Detection, care pathways, and emerging therapies

Low magnification microscopic image of a desmoid tumor in purple with a pink background.

DGHO 2025: Desmoid tumor updates

Experts discuss desmoid tumor care at DGHO 2025

Audience listening to a speaker at a podium during a presentation

ACR 2025 highlights

Biomarker-driven breakthroughs in MAS and HLH

Microscopic image of tissue showing purple cells on a pink background.

EANO 2025: NF1 insights

Expert interviews on care gaps and treatment updates

AL amyloidosis at ESC 2023

Updates on diagnosis and risk stratification

Key considerations when selecting treatment for patients with AL amyloidosis

Read about the latest research on and management of amyloidosis with highlights from the 18th International Symposium on Amyloidosis (ISA) 2022 from Heidelberg, Germany.

Emerging therapies in advanced AL amyloidosis

Discover in this article an overview of the Satellite Symposium, ‘Addressing the Unmet Need in Advanced AL Amyloidosis: Key insights from a panel of experts.

Unmet medical needs in managing tissue toxicity and organ dysfunction

Read in this article from ISA 2022 an overview of the Satellite Symposium, ‘Unmet Medical Needs in AL Amyloidosis’.

HLH/MAS from ACR 2025

ACR 2025 highlights

Biomarker-driven breakthroughs in MAS and HLH

Myasthenia Gravis from EAN 2024

Individualised treatment for MG

Read about Nils Erik Gilhus’ Moritz Romberg Lecture, real-world data on eculizumab and efgartigimod, and how gender impacts myasthenia gravis.

Gender medicine and MG

Read about the impact of myasthenia gravis on childbirth and why women with myasthenia may go undiagnosed for longer.  

Existing and emerging treatments for MG: Real-world data

Read about a multicentre, retrospective trial, comparing efficacy of a FcRn blocker and a complement inhibitor in people with generalised myasthenia gravis.

AL Amyloidosis from ESC 2023 and ISA 2022